Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash & Current Investments: 2020-2025

Historic Cash & Current Investments for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to $147.3 million.

  • Caribou Biosciences' Cash & Current Investments fell 35.46% to $147.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $749.2 million, marking a year-over-year decrease of 32.66%. This contributed to the annual value of $209.5 million for FY2024, which is 36.28% down from last year.
  • As of Q3 2025, Caribou Biosciences' Cash & Current Investments stood at $147.3 million, which was down 19.95% from $183.9 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year Cash & Current Investments high stood at $435.3 million for Q3 2021, and its period low was $129.5 million during Q2 2021.
  • For the 3-year period, Caribou Biosciences' Cash & Current Investments averaged around $244.4 million, with its median value being $228.5 million (2023).
  • As far as peak fluctuations go, Caribou Biosciences' Cash & Current Investments soared by 2,255.87% in 2021, and later slumped by 36.28% in 2024.
  • Over the past 5 years, Caribou Biosciences' Cash & Current Investments (Quarterly) stood at $375.8 million in 2021, then slumped by 34.10% to $247.7 million in 2022, then surged by 32.77% to $328.8 million in 2023, then plummeted by 36.28% to $209.5 million in 2024, then plummeted by 35.46% to $147.3 million in 2025.
  • Its Cash & Current Investments stands at $147.3 million for Q3 2025, versus $183.9 million for Q2 2025 and $208.5 million for Q1 2025.